Brief: SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium
10/12/2025 13:06
Dec 10 (Reuters) - Scienture Holdings Inc SCNX.O: SCIENTURE AND BLINKRX ANNOUNCE STRATEGIC COLLABORATION TO EXPAND PATIENT ACCESS TO ARBLI™, THE FIRST FDA-APPROVED READY-TO-USE ORAL SUSPENSION OF LOSARTAN POTASSIUM SCIENTURE HOLDINGS INC - ARBLI EXPECTED ON BLINKRX PLATFORM IN Q1 2026 Source text: ID:nGNX8zLbfl Further company coverage: SCNX.O ((Reuters.Briefs@thomsonreuters.com;))